Hepatocellular carcinoma in non-alcoholic steatohepatitis without cirrhosis  

作　　者：Cristiane Valle Tovo Angelo Zambam de Mattos Gabriela Perdomo Coral Giovana D P Sartori Livia Villela Nogueira Gustavo Tovo Both Cristiane A Villela-Nogueira Angelo A de Mattos 

机构地区：[1]Department of Internal Medicine,Universidade Federal de Ciências da Saúde de Porto Alegre,Porto Alegre 90050170,RS,Brazil [2]Department of Internal Medicine,Fundação Técnico Educacional Souza Marques,RJ 21491-630,RJ,Brazil [3]Department of Internal Medicine,Universidade Luterana do Brasil,Canoas 92425-350,RS,Brazil [4]Department of Internal Medicine,Universidade Federal do Rio de Janeiro,Rio de Janeiro 21491-630,RJ,Brazil

出　　处：《World Journal of Gastroenterology》2023年第2期343-356,共14页世界胃肠病学杂志（英文版）

摘　　要：Cirrhosis is an emerging major cause of the development of hepatocellular carcinoma(HCC),but in non-alcoholic fatty liver disease(NAFLD),up to 50%of patients with HCC had no clinical or histological evidence of cirrhosis.It is currently challenging to propose general recommendations for screening patients with NAFLD without cirrhosis,and each patient should be evaluated on a caseby-case basis based on the profile of specific risk factors identified.For HCC screening in NAFLD,a valid precision-based screening is needed.Currently,when evaluating this population of patients,the use of non-invasive methods can guide the selection of those who should undergo a screening and surveillance program.Hence,the objective of the present study is to review the epidemiology,the pathophysiology,the histopathological aspects,the current recommendations,and novel perspectives in the surveillance of non-cirrhotic NAFLD-related HCC.

关 键 词：Non-alcoholic fatty liver disease Non-alcoholic steatohepatitis Hepatocellular carcinoma Genetic variants MICROBIOTA OBESITY 

分 类 号：R735.7[医药卫生—肿瘤] R575.5[医药卫生—临床医学]